Latest News

Keep up to date with the latest news from Pilatus Biosciences.

News

February 19, 2026

Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma

December 15, 2025

Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint Antibody in Solid Tumors

December 8, 2025

Pilatus Biosciences is Selected for LabCentral New Cambridge-Based Educational Program

October 30, 2025

Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012’s Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting

Upcoming Events

March 24, 2026

-

March 25, 2026

QEII Centre, London, UK

NextGen Biomed 2026

More Info